Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Pain 4Pain, Postoperative 3Agnosia 3Ovarian Neoplasms 2Inflammation 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Thyroid Nodule 1Reperfusion Injury 1Rectal Neoplasms 1Prostatic Neoplasms 1Obesity 1Neoplasms 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Ileus 1Goiter 1End Stage Liver Disease 1Emergencies 1Diverticulosis, Colonic 1Diverticulitis, Colonic 1Curative Breast Cancer Surgery 1Constipation 1

Interventions

Exercise 25Metformin 23Tirzepatide 9Resistance Training 8Nutrition Assessment 8Methods 8Diet Therapy 8Diet 8Counseling 8Surveys and Questionnaires 6Early Intervention, Educational 6Caloric Restriction 6semaglutide 5Liraglutide 5Exenatide 5Diet, Mediterranean 5Blood Specimen Collection 5Educational Status 4Docosahexaenoic Acids 4Bariatric Surgery 4exemestane 3Vitamin D 3Therapeutics 3Tamoxifen 3Sugars 3Standard of Care 3Observation 3Naltrexone 3Letrozole 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Obesity × Ketorolac × Clear all
NCT06150898 2025-06-13

KePreSt

Jules Bordet Institute

Phase 2 Recruiting
112 enrolled
BreastOther

Breast Neoplasms, Inflammation, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡